Attached To Carbohydrate Compound; Derivative Thereof (e.g., Dna, Nucleotide, Nucleoside, Sugar, Starch, Tannin, Saccharide, Polysaccharide, Cellulose, O-, N- And S-glycoside, Vitamin B12) Patents (Class 424/1.73)
  • Patent number: 6409987
    Abstract: A selectively targeted agent comprising a dermatan sulfate having more than about 25% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units that is covalently attached or bonded to a radioactive metal-ion binding moiety. The targeted agent is useful in preparing radiagnostic and/or radiopharmaceutical agents for diagnostic and/or therapeutic treatment when combined with an appropriate radioactive metal ion such as 99mTc, 186Re or 188Re.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: June 25, 2002
    Assignee: Intimax Corporation
    Inventors: Alan D. Cardin, Cornelius L. Van Gorp
  • Patent number: 6395256
    Abstract: The invention relates to a method for detecting adenosine with the inactive S-adenosyl homocysteine hydrolase's enzyme which selectively and only binds adenosine with high affinity. The inventive method enables adenosine to be determined in small sample volumes without the need for additional purification of said sample.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: May 28, 2002
    Inventors: Hartmut Osswald, Doris Kloor
  • Publication number: 20020051748
    Abstract: A water-in-oil-in-water (W/O/W) emulsion to be used in an antigen delivery system to induce rapid and long-lasting immunity among populations of livestock, birds, and fish. The external aqueous phase of the W/O/W emulsion contains a thixotropic inorganic salt, such as aluminum hydroxide or alum. The presence of the inorganic salt helps to elicit both a Th1 and a Th2 response from the subject's immune system, and the thixotropic properties of the salt stabilize the water-in-oil-in-water emulsion, thereby providing a longer vaccine shelf life. The antigen dose to be delivered to the subject may be contained in entirely in the internal aqueous phase. Alternatively, a first portion of the total antigen dose may be included in the internal aqueous phase and a second portion is included in the external aqueous phase. The incorporation of a portion of the antigen in the external aqueous phase triggers a more uniform immune response across a vaccinated population.
    Type: Application
    Filed: December 22, 1998
    Publication date: May 2, 2002
    Inventors: WILLIAM C. SNOW, WALTER C. GOGAN
  • Patent number: 6376474
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: April 23, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Joseph S. Heilig, Larry Gold
  • Patent number: 6359119
    Abstract: The invention relates to novel aminocarboxylate ligands that are suitable for complexing with a radionuclide, and are useful as therapeutic agents and as imaging agents for diagnostic purposes. In accordance with the present invention, a method of preparing a compound of formula fac-[M(CO)3(OH2)3]+  (I) wherein M is Mn, 99mTc, 186Re or 188Re, involves reacting a metal in permetallate form with carbon monoxide and stannous ion. The compound of formula (I) can be reacted with a ligand Lx to form a compound of the formula fac-[M(CO)3Lx]n  (II) wherein M is as defined above, Lx is a monodentate or multidentate ligand or a mixture of these ligands, and n is a charge of the ligand Lx increased with one + charge. The invention also is directed to novel compounds, and kits for carrying out the disclosed methods.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: March 19, 2002
    Assignee: Mallinckrodt Inc.
    Inventors: David W. Pipes, Mary E. Dyszlewski, Elizabeth G. Webb
  • Patent number: 6355609
    Abstract: Nutritional solutions and methods of making same are disclosed. The solutions include protein, lipid, and a carbohydrate source including high amylose starch and guar gum.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: March 12, 2002
    Assignee: Nestec S.A.
    Inventors: Chandrasekhara Reddy Mallangi, Eileen Fuchs, Kjerstin Carlsson, Axel Syrbe, Reinhard Behringer
  • Patent number: 6348492
    Abstract: This invention relates to novel oxetanone derivative compounds and processes for producing such derivatives that are useful as lipase inhibitors. Further the invention relates to processes for producing salts and for producing pharmaceutical compositions compounds comprising at least one such oxetanone derivative or salt, as well as methods for using such compounds and compositions for inhibiting lipases.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: February 19, 2002
    Assignee: 2Pro Chemical
    Inventor: John Jason Gentry Mullins
  • Patent number: 6342519
    Abstract: This invention relates to novel oxetanone derivative compounds and processes for producing such derivatives that are useful as lipase inhibitors. Further the invention relates to processes for producing salts and for producing pharmaceutical compositions compounds comprising at least one such oxetanone derivative or salt, as well as methods for using such compounds and compositions for inhibiting lipases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: January 29, 2002
    Assignee: 2 Pro Chemical
    Inventor: John Jason Gentry Mullins
  • Patent number: 6331287
    Abstract: The nucleoside analog 2′-fluoro-5-methyl-1-&bgr;-D-arabinofuranosyluracil (FMAU) has been found to have an especially desirable combination of properties for use as an imaging agent, including in particular limited in vivo catabolism. Methods for the preparation of the [11C]-and [18F]-labeled FMAU and for the use of the labeled material are also provided.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: December 18, 2001
    Assignee: University Advanced Bio-imaging Associates
    Inventors: Peter S. Conti, Mian M. Alauddin, John D. Fissekis
  • Publication number: 20010046470
    Abstract: This invention proposes the existence of an alternate glucose pathway different from that presently accepted and offers different methods of proving this. The proposed alternate glucose pathway considers the cerebral spinal fluid as a major component of the pathway. Based on this, a diagnostic tool for detecting mental disorders and neurological disorders which can not be detected by CT Scan and MRI is proposed. Medications directed at the CSF are also proposed.
    Type: Application
    Filed: May 9, 2001
    Publication date: November 29, 2001
    Inventor: Kieko Morita
  • Patent number: 6306587
    Abstract: Methods, apparatus and compositions are presented for ligating ligands together which bind to a common receptor. One embodiment includes polynucleotide probes having photoreactive functional groups. The probes are capable of assuming substantially contiguous reactive positions on a target polynucleotide placing the photoreactive group in juxtaposition. Activation of the photoreactive functional groups with radiant energy form a probe reaction product in which the probes are bound to each other.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: October 23, 2001
    Assignee: Vysis, Inc.
    Inventors: Garfield P. Royer, Larry E. Morrison, Kenneth A. Cruickshank
  • Patent number: 6303100
    Abstract: Disclosed are methods for inhibiting the formation of potential endoleaks associated with endovascular repair of abdominal aortic aneurysms which comprise the in situ embolization of blood vessels associated with the aneurysmal sac prior to placement of an endovascular prostheses in the abdominal aorta. Embolization of the blood vessels is achieved by injection of either a biocompatible polymer or prepolymer fluid composition into these vessels in a sufficient amount such that upon in situ solidification of this composition, blood circulation through these blood vessels and the aneurysmal sac ceases.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: October 16, 2001
    Assignee: Micro Therapeutics, Inc.
    Inventors: Charlie Ricci, Bart Dolmatch, Andrew H. Cragg, Richard J. Greff
  • Patent number: 6299857
    Abstract: The invention provides cardiovascular imaging agents comprising a radionuclide in association with a nucleotide polyphosphate targeting molecule. Methods for using the cardiovascular imaging agents and kits containing the cardiovascular imaging agents or components suitable for production of the cardiovascular imaging agents are also provided.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: October 9, 2001
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, John W. Babich, Eliezer Rapaport, Paul C. Zamecnik
  • Publication number: 20010024636
    Abstract: The present invention is a thermally reversible stimulus-sensitive gel or gelling copolymer radioisotope carrier that is a linear random copolymer of an [meth-]acrylamide derivative and a hydrophilic comonomer, wherein the linear random copolymer is in the form of a plurality of linear chains having a plurality of molecular weights greater than or equal to a minimum gelling molecular weight cutoff. Addition of a biodegradable backbone and/or a therapeutic agent imparts further utility. The method of the present invention for making a thermally reversible stimulus-sensitive gelling copolymer radionuclcide carrier has the steps of: (a) mixing a stimulus-sensitive reversible gelling copolymer with an aqueous solvent as a stimulus-sensitive reversible gelling solution; and (b) mixing a radioisotope with said stimulus-sensitive reversible gelling solution as said radioisotope carrier.
    Type: Application
    Filed: May 10, 2001
    Publication date: September 27, 2001
    Inventors: Richard E. Weller, Michael A. Lind, Darrell R. Fisher, Anna Gutowska, Allison A. Campbell
  • Patent number: 6287536
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: September 11, 2001
    Assignee: NeoRx Corporation
    Inventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
  • Patent number: 6284220
    Abstract: Nucleic acid-imaging compositions and methods for noninvasive imaging of a nucleic acid introduced into somatic tissues of an animal or human are disclosed. The noninvasive imaging enables quantitative assessment of the biodistribution of the introduced nucleic acid. The disclosed imaging compounds include a base-binding moiety, a phosphate-binding moiety, and a metal-binding moiety. A chelated metal is non-invasively detected for imaging by radioactivity or magnetic resonance.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 4, 2001
    Assignee: The General Hospital Corporation
    Inventors: Alexei Bogdanov, Ching-Hsuan Tung, Ralph Weissleder
  • Patent number: 6280740
    Abstract: Vaccine formulations comprising recombinant early (E) and late (L) proteins of papillomavirus and oxidized mannan as well as methods of making and using the formulations are provided.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 28, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Sunil K. Gupta, George E. Mark, III
  • Patent number: 6270745
    Abstract: The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance. The radioactive transition metal nitride heterocomplex of the present invention is represented by the following formula (I): (M≡N)XY  (I) wherein a radioactive transition metal M is radioactive technetium or radioactive rhenium, N is a nitrogen atom, X is a diphosphine compound or a diarsine compound, and Y is a bindentate ligand having a combination of electron-donating atoms.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: August 7, 2001
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Fiorenzo Refosco, Francesco Tisato
  • Patent number: 6268351
    Abstract: The present invention provides novel methods for stimulating proliferation in auditory receptor epithelium. Administration of agents that activate cAMP production result in demonstrable regeneration of hair cells in the cochlea. These agents may be administered in vivo to restore hearing loss or balance loss in patients in need of such treatment.
    Type: Grant
    Filed: May 27, 1998
    Date of Patent: July 31, 2001
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: J. Carl Oberholtzer, Dhasakumar S. Navarathan
  • Patent number: 6251478
    Abstract: A process for stabilizing a sensitive substance; (a) plating a sensitive substance onto a solid carrier under a controlled atmosphere to reduce loss of the sensitive substance; (b) encapsulating the plated material under controlled atmosphere and airflow to reduce volatilization during the process and stabilize the sensitive substance.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: June 26, 2001
    Assignee: Balchem Corporation
    Inventors: Carl J. Pacifico, Wen-Hsin Wu, Marta Fraley
  • Patent number: 6251405
    Abstract: Immunological compositions and methods for making and using them. The compositions contain an antigen and a lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immurogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 26, 2001
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Robert C. Huebner, Maryann B. Gray, Karen S. Biscardi
  • Patent number: 6245316
    Abstract: A radioimaging material or a radioprotective material is attached to a carbohydrate which is capable of binding to or penetrating a cell. The carbohydrate material can be preferentially taken up by tumor cells and provides for imaging thereof.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: June 12, 2001
    Inventor: David Platt
  • Patent number: 6231832
    Abstract: Radiopharmaceutical compositions including 117mSn labeled stannic (Sn4+) chelates are provided. The chelates are preferably polyhydroxycarboxylate, such as oxalates, tartrates, citrates, malonates, gluconates, glucoheptonates and the like. Methods of making 117mSn-labeled (Sn4+) polyhydroxycarboxylic chelates are also provided. The foregoing pharmaceutical compositions can be used in methods of preparing bone for scintigraphical analysis, for radiopharmaceutical skeletal imaging, treatment of pain resulting from metastatic bone involvement, treatment of primary bone cancer, treatment of cancer resulting from metastatic spread to bone from other primary cancers, treatment of pain resulting from rheumatoid arthritis, treatment of bone/joint disorders and to monitor radioactively the skeletal system.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: May 15, 2001
    Assignee: Brookhaven Science Associates
    Inventors: Suresh C. Srivastava, George E. Meinken
  • Patent number: 6210653
    Abstract: Low molecular weight polystyrenes containing sulfonic acids and their salts or low molecular weight sulfonated polystyrene copolymers used as anti-viral agents against enveloped viruses such as HIV. These compounds have been shown to be effective in in vitro testing against HIV at subtoxic concentrations.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: April 3, 2001
    Inventors: Arturo G. Bellettini, Richard J. Bellettini
  • Patent number: 6207136
    Abstract: A fluorescent imaging method of the changes in viability of living bodies wherein the living bodies are provided with a chemical or physical exterior stimulation and information on the changes in viability of cells caused by the stimulation is obtained by means of a fluorescent imaging method of the saccharide uptake activity by contacting or administering to the living bodies an aqueous solution of a fluorescent saccharide compound which includes at its specific position a saccharide molecule chemically combined with a fluorescent pigment molecule.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: March 27, 2001
    Assignee: Tokyo University of Agriculture and Technology
    Inventor: Hideaki Matsuoka
  • Patent number: 6187286
    Abstract: The invention provides tumor imaging agents comprising a radionuclide in association with a nucleotide polyphosphate targeting molecule. Methods for using the tumor imaging agents and kits containing the tumor imaging agents or components suitable for production of the tumor imaging agents are also provided.
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: February 13, 2001
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, John W. Babich
  • Patent number: 6171577
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeleci annexin conjugates are also provided.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: January 9, 2001
    Assignees: NeoRx Corporation, University of Washington
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • Patent number: 6168778
    Abstract: This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: January 2, 2001
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Nebojsa Janjic, Larry Gold, Paul Schmidt, Chandra Vargeese